Flourish Research
Welcome,         Profile    Billing    Logout  
 3 Trials 
42 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Kimball
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
APPROACH, NCT06564818: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Recruiting
3
220
US
CYB003, Psychological Support, Placebo
Cybin IRL Limited, Worldwide Clinical Trials
Major Depressive Disorder
03/26
05/26
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
NCT06075667: A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Recruiting
3
150
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
10/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
ADHD, NCT06215144: Study to Evaluate NRCT-101SR in Pediatric Subjects with

Recruiting
2/3
160
US
NRCT-101SR, Matching Placebo
Neurocentria, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
12/25
02/26
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT06524830: A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Recruiting
2
142
Canada, US
VLS-01-203 BU, VLS-01-BU Placebo
atai Therapeutics, Inc.
Treatment Resistant Depression
12/25
03/26
NCT06817356: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Recruiting
2
300
US
Mazdutide, LY3305677, Placebo
Eli Lilly and Company
Alcohol Use Disorder
08/26
08/26
NCT06673368: A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Recruiting
2
60
US
NRCT-101SR, NRCT-202XR
Neurocentria, Inc.
ADHD
11/25
11/25
MAD, NCT05363293: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Completed
1/2
65
Canada, US
AL001, Alzamend AL001, Placebo
Alzamend Neuro, Inc.
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
04/23
05/23
NCT06297590: A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
1
32
Europe, Japan, US
LY3954068, Placebo, Flortaucipir F18
Eli Lilly and Company
Alzheimer Disease
02/27
02/27
J5K-MC-OQAA, NCT06657768: A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Recruiting
1
68
US
LY4006895, Placebo
Eli Lilly and Company
Alzheimer Disease, Healthy
07/27
07/27
NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Recruiting
1
128
US
PMN310, Placebo
ProMis Neurosciences, Inc
Alzheimer Disease, Early Onset
07/26
12/26
NCT06618183: Drug Screening System Method Comparison

Recruiting
N/A
135
US
Fingerprint sweat drug screen, Fingerprint sweat laboratory analysis
Intelligent Bio Solutions Inc.
Reagent Kits, Diagnostic
11/24
12/24
Cortez, Nathan
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
NCT06279689: Echography Study_Anthropometric Measurements

Recruiting
N/A
90
US
Ultrasound scans
Crossject
Healthy Subjects
09/24
09/24
Hedges, Parke J
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Active, not recruiting
2
75
US
GLY-200, Placebo
Glyscend, Inc.
Obesity
12/24
12/24
NCT06497127: A Study in Patients with Mixed Dyslipidemia

Recruiting
2
132
US
BW-00112
Shanghai Argo Biopharmaceutical Co., Ltd.
Mixed Dyslipidemia
06/25
09/25
Elfassy, Yael
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
ADHD, NCT06215144: Study to Evaluate NRCT-101SR in Pediatric Subjects with

Recruiting
2/3
160
US
NRCT-101SR, Matching Placebo
Neurocentria, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
12/25
02/26
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06673368: A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Recruiting
2
60
US
NRCT-101SR, NRCT-202XR
Neurocentria, Inc.
ADHD
11/25
11/25
Jesus, Kerry D
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
Wilson, Sierra
NCT06532942: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Recruiting
1
40
US
(Part A) MKND-201, Placebo, (Part B) MKND-201
Mannkind Corporation
Healthy Volunteers
10/24
10/24
NCT06799013: Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Not yet recruiting
1
48
US
10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
HDT Bio, DFNet Research Inc., Technical Resources International, Inc. (TRI), BioAgilytix Labs, LLC, The University of Texas Medical Branch, Galveston, Clinical Trials of Texas, Inc., Quest Laboratories
Vaccine, Crimean-Congo Hemorrhagic Fever
12/26
07/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Kimball
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
APPROACH, NCT06564818: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Recruiting
3
220
US
CYB003, Psychological Support, Placebo
Cybin IRL Limited, Worldwide Clinical Trials
Major Depressive Disorder
03/26
05/26
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
NCT06075667: A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Recruiting
3
150
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
10/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
ADHD, NCT06215144: Study to Evaluate NRCT-101SR in Pediatric Subjects with

Recruiting
2/3
160
US
NRCT-101SR, Matching Placebo
Neurocentria, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
12/25
02/26
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT06524830: A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Recruiting
2
142
Canada, US
VLS-01-203 BU, VLS-01-BU Placebo
atai Therapeutics, Inc.
Treatment Resistant Depression
12/25
03/26
NCT06817356: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Recruiting
2
300
US
Mazdutide, LY3305677, Placebo
Eli Lilly and Company
Alcohol Use Disorder
08/26
08/26
NCT06673368: A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Recruiting
2
60
US
NRCT-101SR, NRCT-202XR
Neurocentria, Inc.
ADHD
11/25
11/25
MAD, NCT05363293: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Completed
1/2
65
Canada, US
AL001, Alzamend AL001, Placebo
Alzamend Neuro, Inc.
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
04/23
05/23
NCT06297590: A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
1
32
Europe, Japan, US
LY3954068, Placebo, Flortaucipir F18
Eli Lilly and Company
Alzheimer Disease
02/27
02/27
J5K-MC-OQAA, NCT06657768: A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Recruiting
1
68
US
LY4006895, Placebo
Eli Lilly and Company
Alzheimer Disease, Healthy
07/27
07/27
NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Recruiting
1
128
US
PMN310, Placebo
ProMis Neurosciences, Inc
Alzheimer Disease, Early Onset
07/26
12/26
NCT06618183: Drug Screening System Method Comparison

Recruiting
N/A
135
US
Fingerprint sweat drug screen, Fingerprint sweat laboratory analysis
Intelligent Bio Solutions Inc.
Reagent Kits, Diagnostic
11/24
12/24
Cortez, Nathan
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
NCT06279689: Echography Study_Anthropometric Measurements

Recruiting
N/A
90
US
Ultrasound scans
Crossject
Healthy Subjects
09/24
09/24
Hedges, Parke J
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Active, not recruiting
2
75
US
GLY-200, Placebo
Glyscend, Inc.
Obesity
12/24
12/24
NCT06497127: A Study in Patients with Mixed Dyslipidemia

Recruiting
2
132
US
BW-00112
Shanghai Argo Biopharmaceutical Co., Ltd.
Mixed Dyslipidemia
06/25
09/25
Elfassy, Yael
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
ADHD, NCT06215144: Study to Evaluate NRCT-101SR in Pediatric Subjects with

Recruiting
2/3
160
US
NRCT-101SR, Matching Placebo
Neurocentria, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
12/25
02/26
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06673368: A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Recruiting
2
60
US
NRCT-101SR, NRCT-202XR
Neurocentria, Inc.
ADHD
11/25
11/25
Jesus, Kerry D
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
Wilson, Sierra
NCT06532942: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Recruiting
1
40
US
(Part A) MKND-201, Placebo, (Part B) MKND-201
Mannkind Corporation
Healthy Volunteers
10/24
10/24
NCT06799013: Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Not yet recruiting
1
48
US
10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
HDT Bio, DFNet Research Inc., Technical Resources International, Inc. (TRI), BioAgilytix Labs, LLC, The University of Texas Medical Branch, Galveston, Clinical Trials of Texas, Inc., Quest Laboratories
Vaccine, Crimean-Congo Hemorrhagic Fever
12/26
07/27

Download Options